
    
      SHX-C301 is a Phase 1, first in human, single-blind, multi-center clinical study to evaluate
      the pharmacokinetics (PK), safety and antidepressant effects of SHX-001 transdermal patch low
      dose delivered based on prediction and high dose delivered based on the estimation from the
      low dose PK in subjects with MDD and sub-optimally controlled by standard of care.
    
  